GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TheraCryf PLC (FRA:8EV) » Definitions » Cyclically Adjusted Price-to-FCF

TheraCryf (FRA:8EV) Cyclically Adjusted Price-to-FCF : (As of May. 21, 2024)


View and export this data going back to 2018. Start your Free Trial

What is TheraCryf Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


TheraCryf Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for TheraCryf's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TheraCryf Cyclically Adjusted Price-to-FCF Chart

TheraCryf Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

TheraCryf Semi-Annual Data
Mar13 Mar14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of TheraCryf's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, TheraCryf's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TheraCryf's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TheraCryf's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where TheraCryf's Cyclically Adjusted Price-to-FCF falls into.



TheraCryf Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

TheraCryf's Cyclically Adjusted FCF per Share for the fiscal year that ended in Mar23 is calculated as:

For example, TheraCryf's adjusted Free Cash Flow per Share data for the fiscal year that ended in Mar23 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar23 (Change)*Current CPI (Mar23)
=-0.017/126.8000*126.8000
=-0.017

Current CPI (Mar23) = 126.8000.

TheraCryf Annual Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -0.013 99.300 -0.017
201503 -0.017 99.600 -0.022
201603 -0.041 100.400 -0.052
201703 -0.051 102.700 -0.063
201803 -0.033 105.100 -0.040
201903 -0.027 107.000 -0.032
202003 -0.022 108.600 -0.026
202103 -0.023 109.700 -0.027
202203 -0.011 116.500 -0.012
202303 -0.017 126.800 -0.017

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


TheraCryf  (FRA:8EV) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


TheraCryf Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of TheraCryf's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


TheraCryf (FRA:8EV) Business Description

Industry
Traded in Other Exchanges
Address
Congleton Road, Suite 24G13- Block 24, Alderley Park, Nether Alderley, GBR, SK10 4TG
Evgen Pharma PLC is a UK-based clinical-stage drug development company. The company is focused on the development of sulforaphane-based compounds. Its core technology is Sulforadex, which synthesis and stabilizes the naturally occurring compound sulforaphane. Geographically, the company operates only in the United Kingdom. It is engaged in the treatment of breast cancer and Subarachnoid Haemorrhage.

TheraCryf (FRA:8EV) Headlines

No Headlines